Mar 28, 2025 | News
Calgary, Alberta, Canada, March 28, 2025 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that, subject to approval of the TSX Venture Exchange...
Mar 17, 2025 | News
Calgary, Alberta – March 17, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announced plans to file for Orphan Drug Designation (ODD) with the U.S. Food and...
Mar 13, 2025 | News
Calgary, Alberta – March 13, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to share part of the final data from its preclinical Rett syndrome...
Mar 11, 2025 | News
Calgary, Alberta – March 11, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today is pleased to announce it will be attending and presenting at the Bloom...
Jan 16, 2025 | News
Calgary, Alberta – January 16, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today is pleased to announce that the Chinese patent office has issued a notice...
Jan 7, 2025 | News
Calgary, Alberta – January 7, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTCQB: MBCOF) (“Marvel” or the “Company”) is pleased to announce that it intends to complete a non-brokered private placement of common shares of the Company...
